KYMR Kymera Therapeutics
- 38.440
- +0.140+0.37%
- 38.430
- -0.010-0.03%
Kymera Therapeutics News
Oppenheimer: The Kymera Therapeutics (KYMR.US) rating was maintained, and the target price was adjusted from better than the market to the better than the market rating, and the target price was adjusted from $53.00 to $52.00.
Kymera Therapeutics Analyst Ratings
Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53
Buy Rating Affirmed for Kymera Therapeutics Backed by Promising KT-253 Program Data and Upcoming ASCO Meeting Anticipation
Kymera Therapeutics (KYMR.US) was first covered by Oppenheimer, giving it an superior market rating, with a target price of $53.00.
Kymera Therapeutics Analyst Ratings
Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53
Truist Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $54
Kymera Therapeutics Analyst Ratings
Kymera Therapeutics (KYMR) Receives a Buy From Truist Financial
Piper Sandler Maintains Overweight on Kymera Therapeutics, Raises Price Target to $56
Kymera Therapeutics Analyst Ratings
Maintaining Hold on Kymera Therapeutics Amidst Promising Pipeline and Industry Challenges
Kymera Therapeutics Analyst Ratings
B. Riley Adjusts Kymera Therapeutics' Price Target to $31 From $16, Keeps Neutral Rating
Stifel Nicolaus Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
Maintaining Hold on Kymera Therapeutics With a Cautious Outlook Amidst Pipeline Progression and Financial Stability
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Morphic Holding (MORF)
Kymera Therapeutics Analyst Ratings
Hold Rating on Kymera Therapeutics Amid Promising R&D but Early-Stage Valuation Uncertainties
Analysis
Price Target
No Data
